Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | WNT1 | P04628 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23077104 | 0.81 | HDAC6 (0.52) | SMN1; SMN2HDAC6HDAC8WNT1GSK3B | |
| SCHEMBL26487314 | 0.81 | NAMPT (0.55) | NAMPT | |
| SCHEMBL26484697 | 0.81 | SMN1; SMN2 (0.50) | NAMPTSMN1; SMN2TAS1R3TAS1R1HTT | |
| SCHEMBL26484688 | 0.80 | HDAC6 (0.51) | HDAC6HDAC8WNT1GSK3BDYRK1A | |
| SCHEMBL20119170 | 0.78 | USP5 (0.47) | SMN1; SMN2HTTHDAC6HDAC8WNT1 | |
| SCHEMBL20119172 | 0.77 | HDAC6 (0.49) | HDAC6HDAC8WNT1GSK3BDYRK1A | |
| SCHEMBL12039308 | 0.76 | MAOA (0.52) | SMN1; SMN2HDAC6HDAC8 | |
| SCHEMBL30839551 | 0.76 | ALDH1A1 (0.61) | HDAC6HDAC8 | |
| SCHEMBL3313430 | 0.76 | ALDH1A1 (0.61) | HDAC6HDAC8 | |
| SCHEMBL3440249 | 0.76 | HDAC6 (0.54) | SMN1; SMN2HDAC6HDAC8WNT1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230323345-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | ARCTURUS THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230323345-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | UPF1, HNRNPUL1, HNRNPUL2 | NAMPT 4410/4885SMN1; SMN2 184/4885TAS1R3 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.